UNION KOREA PHARM Extends Trading Suspension Period Due to Capital Reduction and Delisting Risk
- KOSDAQ Market Division changed the trading suspension period for UNION KOREA PHARM.
- Reason for change is 'investor protection', related to capital reduction and delisting process.
- Original suspension period: April 7, 2026 ~ until court decision on preliminary injunction to suspend delisting.
- Changed suspension period: April 7, 2026 ~ (1) until court decision on injunction, or (2) if change of listing application completed within 1 month of capital reduction event, until new shares listing; if not completed, until day before delisting.
- This indicates UNION KOREA PHARM faces capital reduction and delisting risk, exposing existing shareholders to equity value decline and potential delisting.
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Change in Stock Trading Suspension Period (Investor Protection)
- Company: UNION KOREA PHARM (080720)
- Submission: KOSDAQ Market Division
- Receipt: 05-20-2026
- Under KRX KOSDAQ Market Division